RGC vs AEYE

Analysts rate Regencell Bioscience Holdings Limited (RGC) a "Hold" — based on 4 analyst ratings — the highest consensus in this comparison.

The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Regencell Bioscience Holdings Limited (RGC) delivered a total return of +98.

9%, compared to -63. 7% for AudioEye, Inc. (AEYE). Over 10 years, the gap is even starker: RGC returned +119. 3% versus AEYE's +102. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Regencell Bioscience Holdings Limited (RGC) is the lower-risk stock at 0.

72β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 218% more volatile than RGC relative to the S&P 500. On balance sheet safety, Regencell Bioscience Holdings Limited (RGC) carries a lower debt/equity ratio of 1% versus 15% for AudioEye, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: AudioEye, Inc.

grew EPS 30. 6% year-over-year, compared to 26. 9% for Regencell Bioscience Holdings Limited. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regencell Bioscience Holdings Limited (RGC) is the more profitable company, earning 0.

0% net margin versus -7. 6% for AudioEye, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RGC leads at 0. 0% versus -7. 9% for AEYE. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Regencell Bioscience Holdings Limited (RGC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

72), +119. 3% 10Y return). AudioEye, Inc. (AEYE) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RGC: +119. 3%, AEYE: +102. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RGC (Healthcare) and AEYE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.